Market research
0FY.F Equillium, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 1.8
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US29446K1060
- Market cap
- 128M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 1.8
About
About Equillium, Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 0FY.F discussion.
5 years, 5 months ago
Equillium, Inc is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Equillium, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 17.9% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 8.5% to $-8M since the same quarter in the previous year.
Based on the above factors, Equillium, Inc gets an overall score of 2/5.